AKAP 150 Activators
Chemical activators of AKAP 150 are a class of compounds that indirectly enhance the function of AKAP 150 through the modulation of second messengers and kinases that AKAP 150 is associated with. These activators work by increasing the levels of cAMP or cGMP within the cell, which in turn activates PKA or influences the pathways that converge on the scaffolding function of AKAP 150. For instance, forskolin and PDE inhibitors like Rolipram and Sildenafil indirectly facilitate AKAP 150 activation by elevating intracellular cAMP, thus enhancing PKA activity. Increased PKA activity can potentiate the recruitment and interaction of AKAP 150 with PKA at specific cellular sites, which is essential for the targeted phosphorylation of substrates by PKA.
In addition to modifying second messenger levels, other compounds in this class can influence the phosphorylation state of proteins interacting with AKAP 150, thus affecting its function. For example, okadaic acid by inhibiting phosphatases can lead to a sustained phosphorylated state of proteins, which may indirectly enhance the binding and action of AKAP 150 in signaling complexes. Similarly, anisomycin through activation of JNK pathways can lead to modifications of protein synthesis and stability, indirectly affecting AKAP 150 expression levels. Such compounds provide useful tools in research for dissecting the multiple roles of AKAP 150 in cellular signaling and understanding how enhancing its function can influence cell physiology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Br-cAMP is a cAMP analog that activates PKA. Enhanced PKA activity can lead to greater recruitment of AKAP150 to PKA-specific subcellular domains, potentially augmenting AKAP150's scaffolding function. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly activates adenylyl cyclase, increasing cAMP levels and thus activating PKA. This can lead to increased interaction of PKA with AKAP150, promoting AKAP150's role in organizing PKA signaling. | ||||||
Sp-cAMPS | 93602-66-5 | sc-201571 | 1 mg | $97.00 | 3 | |
Sp-cAMPS is a PKA activator that mimics cAMP. By activating PKA, Sp-cAMPS can indirectly enhance AKAP150's ability to scaffold PKA and influence localized signaling. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a JNK activator that can lead to the phosphorylation of substrates involved in the stabilization of mRNA transcripts, potentially increasing the expression of AKAP150. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits PDE4, leading to increased cAMP levels in cells, which in turn activates PKA. Enhanced PKA activity could strengthen AKAP150-mediated signaling complexes. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, elevating cAMP and cGMP levels. Higher cAMP levels activate PKA, which may boost AKAP150's scaffolding activity. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a protein phosphatase inhibitor that can result in the hyperphosphorylation of various proteins, potentially affecting those that interact with AKAP150, leading to its activation. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine inhibits PDE1, resulting in increased cAMP and cGMP levels. Elevated cAMP enhances PKA activity, potentially amplifying AKAP150's interaction with PKA. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is another PDE5 inhibitor which could increase cAMP levels via cGMP, thereby indirectly enhancing the function of AKAP150 through PKA activation. | ||||||